Related Experiment Video

Updated: Jan 22, 2026

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
06:04

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease

Published on: February 9, 2016

22.1K

siRNA Targeting and Treatment of Gastrointestinal Diseases

Rachel Chevalier1,2

  • 1Children's Mercy Kansas City, Kansas City, Missouri, USA.

Clinical and Translational Science
|July 17, 2019
PubMed

Insights

Small interfering RNA (siRNA) therapies can target gastrointestinal diseases, but delivery is difficult. Polymer and lipid systems show promise for protecting and targeting siRNA to treat localized GI conditions.

Area of Science:

  • Biotechnology
  • Gastroenterology
  • RNA Therapeutics

Background:

  • Small interfering RNA (siRNA) holds potential for treating gastrointestinal (GI) pathologies like inflammatory bowel disease and celiac disease.
  • Effective delivery of siRNA to the GI tract is hindered by the intestinal environment and the need for site-specific targeting.

Purpose of the Study:

  • To review polymer and lipid-based delivery systems for siRNA in the GI tract.
  • To discuss strategies for protecting siRNA and targeting it to specific sites for localized GI disease treatment.

Main Methods:

  • Literature review of polymer and lipid-based delivery systems for siRNA.
  • Analysis of challenges in GI siRNA delivery, including degradation and targeting.

Main Results:

  • Polymer and lipid-based systems offer potential for protecting siRNA from degradation in the GI tract.
  • These systems can be engineered for targeted delivery to specific sites within the GI tract.

Conclusions:

  • Advanced delivery systems are crucial for realizing the therapeutic potential of siRNA in GI diseases.
  • Targeted delivery of siRNA using polymer and lipid carriers can overcome GI tract barriers for localized treatment.

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.1K
A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System05:28

A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System

Published on: August 15, 2019

25.2K

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
841
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
452
Anatomy of the Gastrointestinal System01:26

Anatomy of the Gastrointestinal System

The human digestive system is an intricate and essential network for nutrient absorption and waste elimination. It encompasses the gastrointestinal (GI) tract and several accessory organs.
Here's a detailed walkthrough of this complex system:
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
505